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Clinical breakpoints (CBPs) have not been established for theMucorales and any antifungal agent. In lieu of CBPs, epidemio-
logic cutoff values (ECVs) are proposed for amphotericin B, posaconazole, and itraconazole and fourMucorales species. Wild-
type (WT)MIC distributions (organisms in a species-drug combination with no detectable acquired resistance mechanisms)
were defined with available pooled CLSI MICs from 14 laboratories (Argentina, Australia, Canada, Europe, India, Mexico, and
the United States) as follows: 10 Apophysomyces variabilis, 32 Cunninghamella bertholletiae, 136 Lichtheimia corymbifera, 10
Mucor indicus, 123 M. circinelloides, 19 M. ramosissimus, 349 Rhizopus arrhizus, 146 R. microsporus, 33 Rhizomucor pusillus,
and 36 Syncephalastrum racemosum isolates. CLSI broth microdilution MICs were aggregated for the analyses. ECVs compris-
ing>95% and>97.5% of the modeled populations were as follows: amphotericin B ECVs for L. corymbiferawere 1 and 2g/ml,
those forM. circinelloides were 1 and 2g/ml, those for R. arrhizus were 2 and 4g/ml, and those for R. microsporus were 2 and
2g/ml, respectively; posaconazole ECVs for L. corymbifera were 1 and 2, those forM. circinelloides were 4 and 4, those for R.
arrhizus were 1 and 2, and those for R. microsporus were 1 and 2, respectively; both itraconazole ECVs for R. arrhizus were 2g/
ml. ECVsmay aid in detecting emerging resistance or isolates with reduced susceptibility (non-WTMICs) to the agents
evaluated.
Although infections caused by filamentous fungi (molds) arenot as prevalent as yeast infections, an increased incidence of
systemic infections caused by Aspergillus and other mold species
andmore recently bymembers of theMucorales (Zygomycetes) has
been documented (1–3). The order Mucorales comprises a vast
variety of genera and species which have been recently reclassified
according to DNA barcoding and internal transcribed spacer
(ITS) ribosomal sequencing (4). AlthoughmostMucorales species
are saprophytic, a large number of these species have been known
to cause severe infections (mucormycosis, previously described as
zygomycosis), especially among immunocompromised patients
and/or patients with granulocytopenia, diabetes, and penetrating
trauma (5–7). The recommended therapy for infections caused by
theMucorales is usually surgery and/or one of the amphotericin B
lipid formulations; despite its toxicity, amphotericin B deoxy-
cholate continues to be used routinely in some areas (5, 8). More
recently, posaconazole has been recommended as salvage therapy
and/or prophylaxis (9–11); itraconazole and other triazoles are
also used as prophylactics (9). Despite antifungal therapy, mucor-
mycosis is associated with a great deal of morbidity and about a
50%mortality rate; breakthrough infections caused by Mucorales
species among patients receiving triazole prophylaxis, especially
voriconazole, are frequently reported (3, 6).
The Clinical and Laboratory Standards Institute (CLSI) Sub-
committee on Antifungal Susceptibility Tests has developed a re-
producible procedure for the antifungal susceptibility testing of
Mucorales species as described in theM38-A2 brothmicrodilution
document (12). However, although species-specific formal clini-
cal breakpoints (CBPs) and/or epidemiological cutoff values
(ECVs) have been established for Candida spp. and Aspergillus
spp. (13–16), neitherMICdistributions nor ECVs are available for
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any Mucorales species. The establishment of CBPs for mold spe-
cies has been hampered by the low incidence of these infections
and the scarcity of the data required for their development, in-
cluding both low andhighMICs thatmight predict clinical failure.
However, ECVs are calculated based onMIC distributions (100
MICs/species/agent) from multiple independent laboratories
(3) (14, 16, 17). Although amphotericin B and triazoleMICdata
have been reported for a variety of genera belonging to theMuco-
rales, available data are mostly for the more prevalent species, and
the number of isolates evaluated is small (18–22).
The purpose of the study was (i) to define wild-type (WT)
susceptibility endpoint MIC distributions of 10Mucorales species
using CLSI M38-A2 broth microdilution MIC data originating
from 3 to 14 laboratories and (ii) to propose ECVs for amphoter-
icin B, posaconazole, and itraconazole for four common Muco-
rales species (Lichtheimia [Absidia] corymbifera, Mucor circinel-
loides, Rhizopus arrhizus [Rhizopus oryzae], and Rhizopus
microsporus) when the number of CLSI MICs was 112 for the
species/agent combination originating from8 independent lab-
oratories. Amphotericin B, posaconazole, and itraconazole MIC
distributions comprising 10 to 93 isolates for the less prevalent
species (e.g., Apophysomyces variabilis, Cunninghamella bertholle-
tiae,Mucor indicus,Mucor ramosissimus, Rhizomucor pusillus, and
Syncephalastrum racemosum) also are documented. We aggre-
gated a total of 10 to 349 MICs (species and antifungal agent de-
pendent) obtained in 14 independent laboratories (Argentina,
Australia, Canada, Europe, India, Mexico, and the United States).
MATERIALS AND METHODS
Isolates. The isolates evaluated were recovered from patients with mostly
five types of infection: rhinocerebral, pulmonary, skin, bone, cerebral
(sometimes both cerebral and cutaneous or pulmonary and cutaneous),
and abdominal. The most common clinical specimens were nasal or pal-
ate biopsy specimens, aspirates, swabs, or scrapes; pulmonary secretions;
pleural fluids; computed tomography-guided fine-needle aspirates; and
bronchoalveolar lavage and endotracheal aspirates. Antifungal suscepti-
bility testing was performed according to the CLSI broth microdilution
method (M38-A2) at the followingmedical centers: VCUMedical Center,
Richmond, VA; Department of Medical Microbiology, Postgraduate In-
stitute of Medical Education and Research, Chandigarh, India; Vallabhb-
hai Patel Chest Institute, University of Delhi, Delhi, India; Instituto Na-
cional de Enfermedades Infecciosas Dr. C. G. Malbrán, Buenos Aires,
Argentina; Institut National de Santé Publique duQuébec, Laboratoire de
Santé Publique du Québec, Sainte-Anne-de-Bellevue, Québec, Canada;
University of Texas Health Science Center, San Antonio, TX; University
Hospitals of Cleveland and Case Western Reserve University, Cleveland,
OH; Universidad Autónoma de Nuevo León, Monterrey, Nuevo León,
México; Facultat deMedicina, IISPV, URV, Reus, Spain; NationalMycol-
ogy Reference Centre, SA Pathology, Adelaide, Australia; The Innsbruck
Medical University, Innsbruck, Austria; Department ofMedical Microbi-
ology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen,
The Netherlands; Hospital General Universitario Gregorio Marañón,
School of Medicine-Universidad Complutense, Madrid, Spain; and the
Università degli Studi di Milano, Milan, Italy. Identification of isolates in
each laboratory was performed usingmolecularmethods or both conven-
tional and molecular identification (5, 7, 23). Isolates were not evaluated
for either azole or amphotericin B resistancemechanisms. Themaximum
numbers of available pooled CLSIMICs from the 14 laboratories for each
species were as follows: 10 for A. variabilis, 32 for C. bertholletiae, 136 for
L. corymbifera, 10 forM. indicus, 123 forM. circinelloides, 19 forM. ramo-
sissimus, 349 for R. arrhizus, 146 for R. microsporus, 33 for Rhizomucor
pusillus, and 36 for S. racemosum (Tables 1, 2, and 3). Although some
laboratories submitted separate data for two varieties of R. microsporus,
ITS sequencing of the varieties of this species has indicated that they are
identical (4); therefore, we pooled all these MICs under R. microsporus as
listed in Tables 1 to 4.Overall, these isolates represented the unique isolate
recovered from each infection and were likely WT strains, but there is no
information regarding the prior exposure to antifungal therapy. This
could be a possible limitation of the study, as prior exposuremay result in
acquired antifungal resistance, skewing the results.
Three quality control (QC) strains,Candida parapsilosisATCC 22019,
Candida krusei ATCC 6258, and Paecilomyces variotii ATCC MYA-3630,
and one reference isolate, Aspergillus flavus ATCC 204304, were used by
the participant laboratories (12, 13).
Antifungal susceptibility testing. In order to include MIC results in
the set of aggregated data from the 14 laboratories (Tables 1 to 3), ampho-
tericin B and triazole MICs were obtained at each center by following the
CLSIM38-A2 brothmicrodilutionmethod (RPMI 1640 broth containing
0.2% dextrose, inoculum concentrations of 104 CFU/ml, and 24 h of
incubation) (12). The MICs were the lowest drug concentrations that
showed 100% growth inhibition or the first clear well compared to the
growth control. At least one of the three QC or reference strains were
utilized during the years of testing in each center; these MICs were within
the recommended MIC limits (13) with one exception. The agreement
was 97% forC. krusei and amphotericin B (one dilution lower than estab-
lished range), but the modes were within one dilution.
Definitions. The WT population is the subpopulation of isolates in a
species-drug combination without detectable acquired resistance mecha-
nisms (17). The ECV is the highest WT susceptibility endpoint; this end-
point has also been defined as the WT cutoff value (COWT).
TABLE 1MIC distributions of amphotericin B for 10 Mucorales species from 3 to 13 laboratories, determined by using the CLSI M38-A2
microdilution method
Species
No. of isolates
tested/no. of
labs
No. of isolates with MIC (g/ml) ofa:
0.03 0.06 0.125 0.25 0.5 1.0 2.0 4.0 8.0 16 32
A. variabilis 10/3 1 1 3 5
C. bertholletiae 32/6 1 1 5 16 8 1
L. corymbifera 136/12 7 17 36 53 19 3 1
M. circinelloides 123/13 1 4 14 42 44 18
M. indicus 10/5 1 3 4 1 1
M. ramosissimus 19/5 2 4 3 6 1 1
R. arrhizus 257/12 1 3 9 26 64 112 39 3
R. pusillus 33/9 2 6 9 12 1 2 1
R. microsporus 146/10 2 11 15 62 38 15 3
S. racemosum 35/5 8 16 3 6 2
a The highest number in each row (showing the most frequently obtained MIC or mode) is in boldface.
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In other words, the ECV is the critical drug concentration that may
identify those strains with decreased susceptibility to the agent being eval-
uated or the non-WT isolates harboring resistant mechanisms (14,
16, 17).
Data analysis. The MIC distribution of each species-agent combina-
tion from each laboratory was listed in an Excel spreadsheet; theMIC data
were reviewed for obvious outlier results and abnormalities, e.g., skewed
distributions (“truncated” [mode at the lowest concentration tested] or
bimodal distributions within an apparent wild type). These abnormal
distributions were not included in the analysis, and outliers were not
observed. Next, the presumptive WT modal MICs were determined for
each species-agent combination and laboratory followed by obtaining the
pooledMIC distributions for each antifungal agent andMucorales species
with the qualifying data. ECVs were calculated for each distribution and
species by the previously reported iterative statistical technique (17).
Briefly, the modeled population is based on fitting a lognormal distribu-
tion to increasing subsets of the data starting at that population that in-
cludes isolates with MICs one dilution higher than the mode (or than the
lower mode if there was more than onemode) and determining the mean
and standard deviation of the cumulative lognormal distribution that best
fits those data; those numbers were used to calculate the MIC that cap-
tures at least 95% and 97.5% of the modeled WT population (not the
observed MIC population). In addition, we evaluated the inherent vari-
ability (approximately within one doubling dilution) of susceptibility
testing and the presence of outlier laboratories in each pooled distribution
(24).
RESULTS AND DISCUSSION
For susceptibility testing to be useful in the clinical setting, MIC
results should be reliable and must classify the infecting isolate as
either resistant (nontreatable) or susceptible (treatable) to the an-
timicrobial agent being evaluated (25, 26). So far, we do not have
susceptibility endpoints that would allow such classification for
any combination of an antifungal agent and a species belonging to
the order Mucorales. The data needed to propose CBPs for these
species and any antifungal agent are not available. However, we
have gathered sufficient CLSI MICs to propose ECVs of ampho-
tericin B and two triazoles and for four species ofMucorales and to
provide MIC distributions for another six less prevalent species.
While a total of 15 laboratories submittedMICs of amphotericin B
and both triazoles, the distributions for between 1 and 2 labora-
tories (depending on the antifungal agent and species) were not
included in the final analysis due to truncated (modal MIC at the
lowest concentration tested) or bimodal (“saddle” between two
modes) distributions; itraconazole data were not provided by
some laboratories. In addition, several data from one of the labo-
ratories were omitted due to the use of RPMI broth with 2% glu-
cose (rather than 0.2% prescribed by CLSI) (12). Although some
of the laboratories also submitted voriconazole data, most of the
modalMICs for the different species were 16g/ml; the exception
was the voriconazole mode of 8 g/ml for 235 isolates of R. arrhi-
zusoriginating in 11 laboratories (data not shown inTables 1 to 3).
The resulting pooled MIC distributions for the three agents
and species evaluated as submitted by 3 to 14 laboratories are
depicted in Tables 1 to 3. Evaluation of the pooled MIC distribu-
tions indicated that themajority of distributions for each antifun-
gal agent and species were typical forWT organisms (3 to 5 2-fold
dilution concentrations surrounding themodalMIC) and that the
distributions from each laboratory were comparable as their
TABLE 2MIC distributions of posaconazole for 10 Mucorales species from 3 to 14 laboratories, determined by using the CLSI M38-A2
microdilution method
Species
No. of isolates
tested/no. of
labs
No. of isolates with MIC (g/ml) ofa:
0.03 0.06 0.125 0.25 0.5 1.0 2.0 4.0 8.0 16 32
A. variabilis 10/3 1 1 7 1
C. bertholletiae 30/6 4 18 8
L. corymbifera 112/13 3 9 26 51 21 1 1
M. circinelloides 120/12 2 2 9 21 49 26 5 2 4
M. indicus 10/5 2 3 3 1 1
M. ramosissimus 13/4 4 4 2 2 1
R. arrhizus 349/14 1 5 14 80 154 57 27 5 4 2
Rhizomucor pusillus 33/9 1 4 10 10 7 1
R. microsporus 137/11 3 12 34 60 21 4 1 2
S. racemosum 36/5 1 2 4 10 11 5 1 2
a The highest number in each row (showing the most frequently obtained MIC or mode) is in boldface.
TABLE 3MIC distributions of itraconazole for 7 Mucorales from 4 to 9 laboratories, determined by using the CLSI M38-A2 microdilution method
Species
No. of isolates
tested/no. of
labs
No. of isolates with MIC (g/ml) ofa:
0.03 0.06 0.125 0.25 0.5 1.0 2.0 4.0 8.0 16 32
C. bertholletiae 25/4 4 4 10 7
L. corymbifera 93/9 5 10 24 21 23 6 3 1
M. circinelloides 49/8 4 3 7 12 15 5 3
R. arrhizus 215/8 4 9 40 85 37 29 2 4 5
Rhizomucor pusillus 14/5 2 4 4 3 1 1
R. microsporus 74/6 1 1 6 15 25 20 1 1 4
S. racemosum 26/5 4 3 5 7 4 1 2
a The highest number in each row (showing the most frequently obtained MIC or mode) is in boldface.
ECVs for Mucorales and Antifungal Agents
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modal MICs for each species-agent combination were mostly
within 1 2-fold dilution of one another. The exceptions were am-
photericin B modes for R. arrhizus (modes of 0.5 to 1 g/ml in 11
of 12 laboratories, while the mode was 0.25 g/ml in one labora-
tory) and itraconazole modes for L. corymbifera (modes of 0.25 to
0.5g/ml in 8 of 9 laboratories, while themodewas 1g/ml in one
laboratory (data not shown in Tables 1 and 3). The latter modal
discrepancy accounts for the three similar “bars” observed in the
pooled itraconazole and L. corymbifera distribution (Table 3).
Amphotericin B modes were species dependent and ranged from
0.06g/ml (S. racemosum) to 2g/ml (C. bertholletiae) (Table 1).
In contrast to amphotericin B,most posaconazolemodes were 0.5
g/ml; the exceptions were modes of 0.25 g/ml (R. pusillus) and
1g/ml (M. circinelloides andA. variabilis). Physiological, genetic,
and morphological data have indicated that the most clinically
relevant species is A. variabilis (27). Data submitted for two other
species in this genus (Apophysomyces ossiformis and Apophysomy-
ces trapeziformis) were insufficient to list in Tables 1 to 3. A wider
modal range (0.25 to 4 g/ml) was observed with itraconazole, as
it was for amphotericin B, among the fewer species evaluated, with
the lower mode for L. corymbifera, R. pusillus, and S. racemosum
and the highest value for M. circinelloides, as it was for posacona-
zole (Tables 2 and 3). Again, some of these distributions are small.
On thewhole, these results underline the need for identification to
the species level as well as for antifungal susceptibility testing.
The in vitro activities of the three antifungal agents evaluated
are similar to those previously reported for most of the species. In
some instances, the pooled amphotericin B MIC ranges were
wider for L. corymbifera, M. circinelloides, and R. pusillus than
previously reported (MIC range for the three species, 0.03 to 16
g/ml [Table 1] versus 0.01 to 0.5 g/ml) (19, 21, 22), but the
number of isolates for these three species was lower (5 to 20 iso-
lates) in those studies and therefore not a good representation of
their susceptibility to amphotericin B. A similar discrepancy in
MIC ranges was also observed with the triazole data (21, 22), but
the most frequent MIC (when provided) was similar to those in
the present study. In contrast, in our pooled distributions of C.
bertholletiae (Tables 1 to 3), the highest MICs of the three agents
ranged between 1 and 8g/ml, versus reported values of 8 to64
g/ml for sets of7 isolates (19, 21). Based on these data and the
widespread geographical area from which we received our MIC
data, we surmise that the data are valid.
The CLSI has made a final decision regarding what ECV per-
centage (the 95% or the 97.5% value) to recommend in the
CLSI document that is under development for this purpose; the
lower percentage risks classifying some WT isolates as non-WT
isolates, while the selected higher ECV percentage risks classifying
some isolates with acquired resistance mechanisms as WT. Be-
cause of that, Table 4 depicts amphotericin B, posaconazole, and
itraconazole ECVs for the aggregated distributions of four species
ofMucorales where the data originated in 8 to 14 laboratories and
comprised100MICs for each species and agent evaluated (using
the methods that comprised 95% and 97.5% of the modeled
populations). The CLSI amphotericin B ECV comprising 95%
of the modeled populations is 1 g/ml for L. corymbifera and M.
circinelloides and 2g/ml for R. arrhizus and R. microsporus; how-
ever, ECVs comprising97.5% of the modeled populations were
one dilution higher with the exception of R. microsporus (both
ECVswere 2g/ml). It is noteworthy that an amphotericin BMIC
of 2 g/ml is anecdotally considered to be the “breakpoint” for
resistance and yet here and among some Aspergillus spp. (15) may
be perceived as a WT value. The ECV of posaconazole for L. co-
rymbifera, R. arrhizus, and R. microsporus is 1 g/ml (comprising
95%of themodeled populations), while the ECV forM. circinel-
loides is 4 g/ml. Posaconazole ECVs comprising 97.5% of the
modeled populations were also one dilution higher, with the ex-
ception of the ECV of 4 g/ml for M. circinelloides. Regarding
itraconazole, we are proposing a 2-g/ml ECV for R. arrhizus,
encompassing both 95% and 97.5% of the modeled popula-
tions. We did not receive sufficient itraconazole data to propose
ECVs for any other species or to propose amphotericin B and
posaconazole ECVs for the less prevalent species. Nevertheless,
the distributions for the species for which ECVs were not pro-
posed of the three agents are depicted in Tables 1 to 3.
The frequency of amphotericin B and triazole MICs above the
ECV (non-WT) varied according to the distribution analyzed
(Table 4); it was lower for all species versus amphotericin B (0% to
2.9%) than for all species versus posaconazole (0.9% to 10.9%)
(ECVs encompassing 95% and 97.5% of the MIC popula-
tions). As expected, the95% analysis provided the highest rates
of non-WTMICs: 2.9% among L. corymbifera versus amphoteri-
cin B and 10.9% for R. arrhizus and posaconazole. Acquired azole
resistance in mold isolates has been studied mostly in Aspergillus
isolates. Targeted disruption of the cyp51A gene in azole-suscep-
tible A. fumigatus isolates has yielded strains with decreased azole
susceptibility (MICs  2 g/ml) and a reduced concentration of
intracellular drug; triazoleMICs of4g/ml for isolates ofAsper-
gillus spp. are associated with clinical failure (28). In a similar
manner, the relationship between resistance mechanisms, high
TABLE 4 Epidemiologic cutoff values (ECVs) for amphotericin B,
posaconazole, and itraconazole and four Mucorales species, obtained in
8 to 14 laboratories by the CLSI M38-A2 broth microdilution methoda
Species
Antifungal
agentb
MIC (g/ml)
Calculated
statistical ECV (g/
ml) (% of MICs
above the ECV, or
non-WT)c
Range Moded 95% 97.5%
L. corymbifera AMB 0.06–16 0.5 1 (2.9) 2 (0.7)
POS 0.06–4 0.5 1 (1.8) 2 (0.9)
ITR 0.06–8 0.25 ND ND
M. circinelloides AMB 0.03–4 0.25 1 (0) 2 (0)
POS 0.06–16 1 4 (5) 4 (5)
ITR 0.25–16 4 ND ND
R. arrhizus AMB 0.03–4 1 2 (1.2) 4 (0)
POS 0.03–32 0.5 1 (10.9) 2 (3.2)
ITR 0.06–16 0.5 2 (5.1) 2 (5.1)
R. microsporus AMB 0.06–4 0.5 2 (2.1) 2 (2.1)
POS 0.06–16 0.5 1 (5.1) 2 (2.2)
ITR 0.25–32 1 ND ND
a ECVs were defined only for distributions from at least three laboratories using RPMI
1640 as described in CLSI document M38-A2 (12).
b AMB, amphotericin B; POS, posaconazole; ITR, itraconazole.
c Calculated ECV comprising95 or97.5% of the statistically modeled population
for each MIC distribution. ND, not determined due to insufficient numbers of
laboratories and isolates/species.
d MIC most frequently obtained for each distribution.
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amphotericin B MICs, and clinical responses to therapy is mostly
available for Aspergillus terreus (intrinsically resistant to this
agent), A. flavus, and some yeast species (29, 30). On the other
hand, antifungal mechanisms of resistance in the Mucorales are
areas that deserve future investigation; to our knowledge, no in-
formation is available regarding resistance mechanisms of either
amphotericin B or posaconazole in these molds despite the fact
that they are the recommended therapeutic agents for mucormy-
cosis. Despite the prolonged use of amphotericin B, its mecha-
nisms of action and/or resistance are not completely understood;
however, overall, resistance to this agent is considered rare. It is
expected that mutations similar to those found in other molds
could be found among non-WT isolates of the Mucorales versus
either amphotericin B or posaconazole.
For these molds and antifungal agents, correlations between
MICs and clinical response to therapy were not found in the liter-
ature, even though large numbers of mucormycosis cases have
been reported. To compound the problem, cultures are not always
available, since other methods of diagnosis are usually performed
to promptly initiate therapy, e.g., histopathology (5, 31). Out-
come is also influenced by the site of infection, the underlying
disease, and other factors. However, the correlation of posacona-
zole MICs and treatment outcome in experimental, disseminated
mucormycosis has been evaluated with a variety ofMucorales spe-
cies. In two of these murine models, immunosuppressed animals
infected with either R. arrhizus or R. microsporus isolates (po-
saconazole MICs, 2 g/ml and 0.25 g/ml for each species), sur-
vival was higher (30 to 40 versus 10 to 20%) when animals were
infected with isolates with the lower MICs (32, 33). In another
study, survival was strain dependent, although posaconazole
MICs for both infected strains were low (0.03 and 0.12 g/ml);
however, posaconazole and amphotericin B prolonged survival
among neutropenicmice infected with an isolate of L. corymbifera
for whichMICs of both agents were 0.06 to 1g/ml (34). Accord-
ing to our proposed posaconazole ECV for L. corymbifera and R.
microsporus, isolates with the lower MICs and good response to
treatment could be considered WT using the values that com-
prised95% of the modeled populations; the same applies to all
infective R. arrhizus isolates (Table 4). The response to posacona-
zole treatment was also found to be uncertain in two M. circinel-
loides models; efficacy was reported as good when survival was
compared to that in nonimmunosuppressed control animals but
variable with regard to reduction of tissue burden (35, 36). The
posaconazole ECV forM. circinelloides is 4g/ml, and the isolates
evaluated in those two studies could be considered either non-WT
(MIC of the infecting isolate, 8 g/ml) (35) or WT (MICs of the
infecting isolates, 1 to 4 g/ml) (36). The MIC in the first study
was determined at 48 h instead of 24 h. Mechanisms of resistance
were not evaluated in any of those strains, because as mentioned
above, the molecular biology of the Mucorales is not as developed
as that of Candida and Aspergillus.
In conclusion, we propose species-specific amphotericin B
ECVs comprising 95% of the modeled populations of 1 g/ml
(L. corymbifera and M. circinelloides) to 2 g/ml (R. arrhizus and
R.microsporus), posaconazole ECVs of 1g/ml (L. corymbifera,R.
arrhizus, andR.microsporus) to 4g/ml (M. circinelloides), and an
itraconazole ECV of 2 g/ml for R. arrhizus. ECVs were mostly
one dilution higher when 97.5% of the modeled populations
was used. Our results cover amphotericin B and its lipid formula-
tions because their MIC data have been comparable (29). Further
studies should determine the relationship between molecular
mechanisms of resistance and our proposed amphotericin B and
triazole non-WT values. Although ECVs do not predict clinical
response to therapy, they should be considered for inclusion in
future CLSI documents regarding the setting and use of ECVs.
Similar to the ECVs for Candida spp. and Aspergillus spp., the
proposed ECVs for the Mucorales may aid in the detection of
strains with acquired mechanisms of resistance (non-WT) to the
agents evaluated in the present study.
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